Comprehensive Research and Investment Value Strategy Consulting Report on Coagulation Factor VII Industry
On October 24, 2024, research firm Global Info Research published the "Global Coagulation Factor VII Industry Overall Size, Key Manufacturers and IPO Research Report, 2024-2030." This report primarily analyzes the overall size of the global coagulation factor VII market, regional sizes, the scale and market share of key enterprises, product category sizes, and downstream application sizes. The size analysis includes revenue and market share. It provides an in-depth analysis of the competitive landscape, revenue, and market share of major enterprises globally, while also focusing on the product characteristics, specifications, revenue, gross margin, market share, and development trends of key manufacturers (brands) in the global market. Historical data covers 2019 to 2023, with forecast data for 2024 to 2030.
Research Firm: Global Info Research Pharmaceutical and Healthcare Research Center
Report Pages: 115
Human coagulation factor VII is a protein that plays a critical role in the blood clotting process (hemostasis). It is one of the key components of the extrinsic pathway of the coagulation cascade, which is activated when tissue damage occurs. The role of coagulation factor VII is to bind with tissue factor (TF) exposed at the injury site, forming a complex that activates other coagulation factors (such as factor X and factor IX), ultimately leading to thrombus formation.
Recombinant human coagulation factor VIIa (rFVIIa) is used as a medication to help control bleeding, particularly for patients with hemophilia or other bleeding disorders who have developed inhibitors to traditional therapies.
According to the latest research by our project team, the global coagulation factor VII market is projected to reach $1.593 billion by 2030, with a compound annual growth rate (CAGR) of 3.6% from 2024 to 2030.
Drivers of the human coagulation factor VII market:
Increasing prevalence of hemophilia and bleeding disorders: Recombinant factor VIIa is primarily used to treat hemophilia, especially in patients with inhibitors to factor VIII or IX. The rising global incidence of hemophilia and other bleeding disorders is a major driver of market demand.
Advances in recombinant technology: Continuous improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of blood-borne pathogen transmission and increase their adoption rate compared to plasma-derived alternatives.
Growing use in trauma and surgical settings: Recombinant factor VIIa is also used to treat severe bleeding during trauma and surgical procedures, further expanding its clinical applications and increasing demand, particularly in emergency care settings.
Rising adoption of off-label uses: Although the primary indication for rFVIIa is hemophilia, it is increasingly being used off-label to treat uncontrolled bleeding in non-hemophilia patients, especially in critical care and trauma settings. This expands its potential market.
Favorable reimbursement policies in developed regions: In regions such as North America and Europe, comprehensive insurance coverage and reimbursement for advanced therapies like rFVIIa make these treatments more accessible to patients, supporting market growth.
Challenges in the human coagulation factor VII market:
High treatment costs: Recombinant factor VIIa therapy is expensive, which may limit access to treatment, particularly in low-income countries and regions with limited healthcare funding or insurance coverage.
Concerns about off-label use: Despite the increasing off-label use of rFVIIa, concerns about its safety and efficacy in non-hemophilia patients have led to caution regarding its broader application. Regulatory scrutiny of off-label use may impact market expansion.
Limited awareness and accessibility in developing regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.
Competition from alternative therapies: Emerging gene therapies, extended half-life coagulation factors, and other innovative hemophilia treatments may compete with or reduce demand for rFVIIa in the future. These newer therapies promise longer-term efficacy or greater convenience.
Regulatory challenges: Strict regulatory approval processes for biologics and ongoing post-market surveillance requirements may slow the introduction of new products or indications, affecting the pace of market growth.
The top three global manufacturers of recombinant coagulation factor VIIa (Recombinant Human Coagulation VIIa) are Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, collectively holding over 99% of the market share. Novo Nordisk is the largest manufacturer, with a market share exceeding 95%. North America is the primary consumption region for recombinant coagulation factor VIIa, accounting for approximately 45% of the global market share.
By product type, coagulation factor VII is segmented into: pre-filled syringes and vials.
By downstream application, this report focuses on the following areas: congenital hemophilia, acquired hemophilia, and others.
This report highlights key global coagulation factor VII manufacturers, including: Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, and GENERIUM.
The scope of this report includes:
Chapter 1: Introduction to the definition of coagulation factor VII products, industry size statistics, product classification, applications, and analysis of global and regional overall sizes and forecasts.
Chapter 2: Focus on enterprises, including basic information, main business and products, introduction to coagulation factor VII products, revenue, gross margin, and latest developments.
Chapter 3: Analysis of global competitive landscape, including revenue, market share, business/product layout, downstream markets and applications, industry mergers and acquisitions, new entrants, and capacity expansion.
Chapter 4: Analysis of global market size by product type for coagulation factor VII, including revenue, forecasts, and market share.
Chapter 5: Analysis of global market size by application for coagulation factor VII, including revenue, forecasts, and market share.
Chapter 6: Segmentation of the North American coagulation factor VII market by country, product type, and application, including revenue and forecasts.
Chapter 7: Segmentation of the European coagulation factor VII market by country, product type, and application, including revenue and forecasts.
Chapter 8: Segmentation of the Asia-Pacific coagulation factor VII market by country, product type, and application, including revenue and forecasts.
Chapter 9: Segmentation of the South American coagulation factor VII market by country, product type, and application, including revenue and forecasts.
Chapter 10: Segmentation of the Middle East and African coagulation factor VII market by country, product type, and application, including revenue and forecasts.
Chapter 11: Comprehensive analysis of market dynamics, drivers, barriers, trends, competitive forces (including existing competitors, potential entrants, supplier bargaining power, buyer bargaining power, and threat of substitutes).
Chapter 12: Industry chain analysis of coagulation factor VII, including upstream raw materials and suppliers, midstream analysis, and downstream analysis.
Chapters 13-14: Research conclusions, methodology, research process, and data sources.
Research Methodology and Data Sources:
This report is based on extensive primary and secondary information collected by the research team. The research process considers various industry factors, including government policies, market environment, competitive landscape, historical data, industry status, technological innovations, related technological developments, market risks, barriers, opportunities, and challenges. Through long-term monitoring of specific industries, the report analyzes demand-side and supply-side characteristics, profitability, industry chains, and business models. It integrates multi-level data and information resources from industries, markets, enterprises, channels, and users to provide clients with in-depth industry market research reports. The report objectively analyzes the overall market size, competitive landscape, segmented data, import/export, and demand characteristics of the industry. It conducts in-depth research on key enterprises, analyzes production and sales operations, and makes objective predictions about future industry trends based on industry trajectories and practical experience. With over a decade of industry research experience, the company employs industry lifecycle theory, SCP analysis models, PEST analysis models, Porter's Five Forces analysis, SWOT analysis models, the Boston Matrix, and Porter's Diamond Model, forming a unique research methodology and industry evaluation system. The table below outlines the market research methods used in this report.
Primary data sources include first-hand information obtained through interviews with key industry enterprises, with interviewees including CEOs, marketing/sales directors, senior executives, industry experts, technical leaders, downstream customers, distributors, agents, dealers, and upstream raw material suppliers. Secondary data sources include global industry news, company annual reports, non-profit organizations, industry associations, government agencies, customs data, and third-party databases.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
